Innovation News Pharma & Biotechnology

Bangladesh allows late-stage trial of China’s Sinovac COVID-19 vaccine

Bangladesh has approved the third-phase trial of a potential COVID-19 vaccine developed by China’s Sinovac Biotech Ltd, officials said on Monday, as infections continue to rise in the densely-populated South Asian country.

Sinovac has been looking for volunteers outside of China country as the number of coronavirus cases there has dwindled, said a member of Bangladesh’s national technical advisory committee to tackle COVID-19.

The International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), will conduct the trial that could begin next month.

“We have given ethical permission for the trial after reviewing the research protocol,” Mahmood Uz Jahan, director of the Bangladesh Medical Research Council (BMRC), told Reuters.

“The protocol given to BMRC by ICDDR,B will be applied to 4,200 volunteers. Half of them will get vaccinated.”

The trial would be conducted in seven COVID-19 hospitals in Dhaka, Bangladesh’s capital, an ICDDR,B official said on the condition of anonymity.

The country had 204,525 confirmed coronavirus cases as of Sunday, with 2,618 deaths.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.